Tag: Alzheimer’s
Memory Preserved in Rare Aphasia Tied to Alzheimer Disease
Decline in language function, but not episodic memory, seen for primary progressive aphasia associated with Alzheimer disease
Experimental Drug for Alzheimer Disease Shows Promise
After six to 12 months of treatment with the drug, patients no longer had amyloid protein plaques
Residential Care Community Characteristics Vary by Dementia Prevalence
Higher prevalence of depression, need for assistance with activities of daily living seen for high proportion of residents with dementia
Alzheimer Disease Tied to Adverse Financial Events
Adverse financial events seen years before diagnosis and become more prevalent after diagnosis
First Blood Test for Alzheimer Disease Available in U.S.
Test from C2N Diagnostics is meant for people 60 years and older who have cognitive issues and are being assessed for Alzheimer disease
RSNA: Anxiety May Hasten Progression to Alzheimer Disease
Rate of progression from MCI to AD increased with ApoE4, anxiety, lower hippocampal and entorhinal cortex volumes
Air Pollution May Up Alzheimer Disease Risk in Elderly
Association seen in older women persisted even at PM2.5 levels below U.S. regulatory standards
Panel Recommends Against Approval of Experimental Drug for Alzheimer Disease
FDA panel concluded there is not enough evidence to support the clinical effectiveness of aducanumab
Multinutrient Intervention Slows Cognitive Decline in Alzheimer Disease
Cognitive decline significantly reduced for Neuropsychological Test Battery five-item composite, memory, brain atrophy measures
Regulators Discuss Approval of New Alzheimer Disease Drug
Aducanumab does not cure or reverse Alzheimer disease; high dose may slow mental decline
